the Statement of Deviation and Variation of proceeds of Public Issue, Right Issue, Preferential Issue, Qualified Institutional Placement, etc. required to be submitted in terms of Regulation 32 of SEBI (LODR) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, is not applicable to Bafna Pharmaceuticals Limited (the Company) for the quarter ended June 30, 2023.